Skip to main content
Equibles
MAJI logo

MAJI · Nextel Medical Corp. · Metrics

Track MAJI — free

Use MAJI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MAJI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 +0.00 (+3.33%) At close · Nov 12
Rebalance outlook locked
Going-concern doubt — flagged Jul 29, 2022

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Jul 29, 2022
Market Cap
$38,726
Shares
12.49M
Volume · Nov 12 315.59K Avg daily vol (3M) 569.77K

MAJI metrics

48 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$38,726

Price action

23 metrics
Price change (1W)
+0.0%
Price change (30D)
-11.8%
Price change (3M)
-66.7%
Price change (6M)
-76.9%
Price change (YTD)
-94.5%
Price change (1Y)
-92.5%
Trailing year
Price change (5Y)
—
52-week high
$0.07
52-week low
$0.00
Change from 52-week high
-95.7%
Change from 52-week low
+15.4%
Annualized volatility
259.9%
Annualized volatility (3M)
195.7%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.2
RSI (14D)
43.3
Price vs SMA 50
-26.8%
Price vs SMA 200
-82.4%
Avg volume (3M)
576,991
Relative volume
2.5
Average dollar volume
$2,689

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
12.49M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,383.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$504,001
Net income (TTM)
−$518,295
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.04
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.04
Operating cash flow per diluted share (TTM)
$-0.01
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.04

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
-1,469.7%
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-51,829.5%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$0
Latest balance sheet
Cash & equivalents
$0
Total assets
$1,000
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$114,752
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$1.07M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
23 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1492448 CUSIP 36257K208 Visit website